12 June - 15 June

EHA2025

MILAN

We are excited to be at EHA2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.

To learn more about our cell therapy abstracts and data, please visit the congress website.

CIBMTR Outcomes in Key Subgroups of 2L Axi-Cel for LBCL
S237

Real-World Effectiveness and Safety Outcomes Among Key Subgroups of Second-Line Axicabtagene Ciloleucel for Patients with Relapsed/Refractory Large B-Cell Lymphoma 

Dasom (Caroline) Lee et al
Friday, 13 June 2026 17:00-18:15 CEST
Immunotherapy in Lymphoma
Click to view full abstract
KITE-363 Ph1 Outcomes (Encore)
S236

A Phase 1 Study of KITE-363 Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B-Cell Lymphoma

Saurabh Dahiya et al
Friday, 13 June 2026 17:00-18:15 CEST
Immunotherapy in Lymphoma
Click to view full abstract
iMM-1 Updated Outcomes
S201

*Kite collaboration

Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma: Updated Results from iMMagine-1

Gurbakhash Kaur et al
Saturday, 14 June 17:00-18:15 PM CDT
Treatment of Relapsed and/or Refractory Multiple Myeloma

ZUMA-3 5-Year Analysis

Five-Year Survival Outcomes of Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Brexucabtagene Autoleucel in ZUMA-3

Olalekan O. Oluwole et al
Friday, June 13 18:30 - 19:30 CEST
Poster Session 1
Click to view full abstract
Treatment Patterns and Economic Outcomes in RRMM

Treatment Patterns and Economic Outcomes in Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma in the US: A Real-World Claims Database Analysis

Doris K Hansen et al
Saturday, 14 June 18:30 - 19:30 CEST
Poster Session 2
RW Outcomes of Brexu-Cel in MCL: SLR and Meta-Analysis

Real-World Outcomes of Brexucabtagene Autoleucel in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Literature Review and Meta-Analysis

Olalekan O. Oluwole et al
Friday, 13 June 18:30 - 19:30 CEST
Poster Session 1
Click to view full abstract
Caregiver Burden in MM

Understanding Caregiver Challenges in Multiple Myeloma: A Systematic Literature Review of the Qualitative and Quantitative Literature

Doris Hansen et al
Friday, 13 June 18:30 - 19:30 CEST
Poster Session 1
Click to view full abstract
Health Impact of CAR T-Cell V2VT in 2L LBCL for Italy

Health Impact of Chimeric Antigen Receptor T-Cell Vein-to-Vein Time in Second-Line Large B-Cell Lymphoma Patients: An Exploratory Modelling Analysis for Italy

Paolo Cortesi et al
Friday, 13 June
Poster Session 1 18:30 - 19:30 CEST
Click to view full abstract
CE of RW Axi-Cel Use in the US

Cost-Effectiveness of Real-World Axicabtagene Ciloleucel Use in Relapsed/Refractory 2L LBCL Based on a Multi-Center US Registry

Olalekan Oluwole et al
Friday, 13 June 18:30 - 19:30 CEST
Poster Session 1
Click to view full abstract
Prognostic Value of ctDNA Detection by PhasED-Seq after Axi-cel Therapy

Prognostic Value of Circulating Tumor DNA Detection by PhasED-Seq After Axicabtagene Ciloleucel Therapy in Relapsed/Refractory Large B-Cell Lymphoma

Brodie Miles et al
Friday, 13 June 18:30 - 19:30 CEST
Poster Session 1
KTE-X19 in R/R ALL in Chinese Population

*Kite collaboration

KTE-X19 in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia in Chinese Population: A Phase 2 Multicenter Study

Meng Lv et al
Friday, 13 June 18:30 - 19:30 CEST
Poster Session 1
Click to view full abstract

Axi-cel Manufacturing Retrospective Analysis From Italy
3238

The Italian Commercial Axi-Cel Manufacturing Performance: A Retrospective Analysis of an Efficient and Reliable Process Over Time

Beatrice Casadei et al
May 14, 2025
1L High-Risk LBCL Outcomes SLR
3238

Clinical, Economic, and Humanistic Outcomes of First-line High-Risk Large B-Cell Lymphoma: A Series of Systematic Literature Reviews

Evan Popoff et al
May 14, 2025